New Zealand awarded 15 oil and gas exploration licenses on Tuesday, with U.S. giant Chevron Corporation (NYSE:CVX) and India’s ONGC Videsh joining the hunt in the South Pacific country for the first time. Chevron is partnering with Norway’s Statoil to explore three prospects off the lightly explored south-east coast of the North Island. Chevron Corporation (NYSE:CVX) belongs to Basic Materials sector. Its net profit margin is 9.80% and weekly performance is -6.15%. On last trading day company shares ended up $107.01. Chevron Corporation (NYSE:CVX) distance from 50-day simple moving average (SMA50) is -6.68%.

Semtech (NASDAQ:SMTC) Director Bruce C. Edwards unloaded 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an average price of $26.00, for a total transaction of $130,000.00. Following the completion of the sale, the director now directly owns 7,000 shares in the company, valued at approximately $182,000. Semtech Corporation (NASDAQ:SMTC) shares increased 1.26% in last trading session and ended the day at $27.37. SMTC Gross Margin is 56.40% and its return on assets is -17.30%. Semtech Corporation (NASDAQ:SMTC) quarterly performance is 0.37%.

On Dec 02, Craft Brew Alliance, Inc. (NASDAQ:BREW) announced it has signed a Letter of Intent (the “Letter”) to form a strategic partnership with Boone, NC-based Appalachian Mountain Brewery, Inc. (“AMB”) Under the terms of the Letter, the two publicly traded companies will explore potential opportunities to drive business growth and shareholder value through sharing resources in key strategic areas including, but not limited to, brewing, purchasing, distribution, and sales. On 09 December, Craft Brew Alliance, Inc. (NASDAQ:BREW) shares increased 3.48% and was closed at $13.66. BREW EPS growth in last 5 year was 15.30%. Craft Brew Alliance, Inc. (NASDAQ:BREW) year to date (YTD) performance is -16.81%.

La Jolla Pharmaceutical Company (NASDAQ:LJPC) announced that La Jolla and GW have entered into an exclusive worldwide license agreement for GW intellectual property rights covering the use of angiotensin II for the therapeutic treatment of patients with hypotension and shock. La Jolla plans to initiate a phase 3 registration program of LJPC-501, La Jolla’s proprietary formulation of angiotensin II, in catecholamine-resistant hypotension (CRH) in the first quarter of 2015. La Jolla Pharmaceutical Co. (NASDAQ:LJPC) ended the last trading day at $11.23. Company weekly volatility is calculated as 4.81% and price to cash ratio as 3.16. La Jolla Pharmaceutical Co. (NASDAQ:LJPC) showed a weekly performance of -2.01%.

Financial services giant JPMorgan Chase & Co. (NYSE:JPM) faces a $22 billion capital shortfall under a new rule proposed by the U.S. Federal Reserve, according to media reports on Tuesday. JPMorgan Chase & Co. (NYSE:JPM) belongs to Financial sector. Its net profit margin is 39.60% and weekly performance is 2.24%. On last trading day company shares ended up $62.45. JPMorgan Chase & Co. (NYSE:JPM) distance from 50-day simple moving average (SMA50) is 4.52%.